Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Pharmacokinetic Study to Evaluate Drug-drug Interactions Between Doravirine-containing ART and Hormonal Contraceptives Among Women Living With HIV in South Africa

Next Previous
X
Search
Trial Profile

An Observational Pharmacokinetic Study to Evaluate Drug-drug Interactions Between Doravirine-containing ART and Hormonal Contraceptives Among Women Living With HIV in South Africa

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doravirine (Primary) ; Doravirine/lamivudine/tenofovir disoproxil fumarate; Etonogestrel; Medroxyprogesterone; Medroxyprogesterone
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms EPIC

    • Most Recent Events

    • 26 Jun 2024 Status changed from active, no longer recruiting to completed.
    • 06 Mar 2024 Results assessing MPA and ETG concentrations and logtransformed concentrations with geometric mean ratios at each visit and safety, tolerability, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 19 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top